Form 4: Quince Therapeutics CBO/COO Granted Stock Options

Brendan Hannah, Quince Therapeutics' CBO, COO, and CCO, was granted 365,000 employee stock options with an exercise price of $3.08.

Summary

• Brendan Hannah, Chief Business Officer, Chief Operating Officer, and Chief Commercial Officer of Quince Therapeutics, Inc. (QNCX), was granted 365,000 employee stock options.
• The options have an exercise price of $3.08 per share.
• The grant date for these options was January 23, 2026.
• The options begin vesting on January 23, 2026, with 1/48th vesting on the grant date and the remainder vesting on the 1st day of each subsequent month.
• The options will be fully vested by December 1, 2029.
• The expiration date for these options is January 23, 2036.
• Following this transaction, Brendan Hannah beneficially owns 365,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event. The grant of stock options is generally viewed as a positive for aligning executive and shareholder interests, but it does not provide new information on company performance or strategic direction.

Positives

• The grant of stock options aligns the executive's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• Potential for future dilution if all options are exercised.

Risks

• No specific risks are mentioned in this Form 4 filing. The inherent risk of stock options is that they may not become in-the-money if the stock price does not rise above the exercise price.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, focusing solely on an executive's equity transaction.

Industry Context

The grant of employee stock options is a standard practice in the biotechnology and pharmaceutical industries, commonly used to attract, retain, and incentivize key executives. This compensation structure aims to align management's financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The grant of stock options to senior executives like a CBO/COO is a common compensation tool across the biotech and pharma sectors, similar to practices at companies such as Amgen, Gilead Sciences, or Moderna.
• The vesting schedule, typically over several years (in this case, approximately 4 years), is standard for ensuring executive retention and long-term commitment, comparable to equity grants at peer companies.
• An exercise price equal to the stock's fair market value on the grant date (implied by the $0 price of the derivative security itself and the $3.08 exercise price) is typical for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation. Potential for future dilution if options are exercised.
• Employees: May signal confidence in the company's future, potentially boosting morale.

Next Steps

• Continued vesting of the 365,000 employee stock options through December 1, 2029.
• Potential exercise of vested options by Brendan Hannah prior to the January 23, 2036 expiration date.

Key Dates

Keywords

Quince Therapeutics, QNCX, Brendan Hannah, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Biotechnology, Pharmaceuticals